Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
64
DYN Quote, Financials, Valuation and Earnings
Last price:
$20.64
Seasonality move
:
4.74%
Day range:
$19.63 - $21.09
52-week range:
$6.36 - $29.72
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.15x
Volume:
2.5M
Avg. volume:
2.9M
1-year change:
-29.86%
Market cap:
$2.9B
Revenue:
--
EPS (TTM):
-$3.66
Analysts' Opinion
-
Consensus RatingDyne Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.38, Dyne Therapeutics, Inc. has an estimated upside of 76.08% from its current price of $20.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 45.25% downside risk from its current price of $20.65.
Fair Value
-
According to the consensus of 13 analysts, Dyne Therapeutics, Inc. has 76.08% upside to fair value with a price target of $35.38 per share.
DYN vs. S&P 500
-
Over the past 5 trading days, Dyne Therapeutics, Inc. has underperformed the S&P 500 by -3.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Dyne Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dyne Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Dyne Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Dyne Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Dyne Therapeutics, Inc. reported earnings per share of -$0.76.
Enterprise value:
2.2B
EV / Invested capital:
2.71x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-1.99x
EV / Free cash flow:
-5.54x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.5M
Return On Assets:
-56.1%
Net Income Margin (TTM):
--
Return On Equity:
-64.85%
Return On Invested Capital:
-59.17%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$2.5M | -$1.8M | -$2.5M | -$400K | -$500K | |
| Operating Income | -$214.6M | -$314.5M | -$449.2M | -$105.7M | -$113.9M | |
| EBITDA | -$212.1M | -$312.7M | -$446.6M | -$105.3M | -$113.4M | |
| Diluted EPS | -$3.59 | -$3.56 | -$3.66 | -$0.96 | -$0.76 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $424.7M | $258.2M | $168.2M | $736.4M | $806.3M | |
| Total Assets | $466.9M | $299.7M | $205.2M | $768.8M | $867.1M | |
| Current Liabilities | $23.4M | $23.3M | $29.7M | $43.3M | $59.8M | |
| Total Liabilities | $52.8M | $49.9M | $53.2M | $63.3M | $175.3M | |
| Total Equity | $414.1M | $249.7M | $152M | $705.5M | $691.8M | |
| Total Debt | $34M | $26.6M | $23.5M | $20M | $115.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$182.3M | -$243M | -$375.7M | -$74.6M | -$90.8M | |
| Cash From Investing | $76.4M | -$161.9M | -$45.7M | -$19.4M | -$38M | |
| Cash From Financing | $91.4M | $806.4M | $463M | $18M | $217.3M | |
| Free Cash Flow | -$183.5M | -$244.4M | -$397M | -$74.9M | -$110M | |
DYN
Sector
Market Cap
$2.9B
$28.4M
Price % of 52-Week High
67.61%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-21.27%
-1.32%
1-Year Price Total Return
-28.68%
-22.19%
Beta (5-Year)
1.302
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$20.86
200-day SMA
Buy
Level
$13.08
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$20.05
Relative Strength Index (RSI14)
Buy
Level
53.80
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-53.7897
50-day SMA
Buy
Level
$18.14
MACD (12, 26)
Buy
Level
0.58
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (21.0636)
Sell
CA Score
(Annual)
Level (-2.5158)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (8.0794)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, DYN has received 10 Buy ratings 3 Hold ratings, and 0 Sell ratings. The DYN average analyst price target in the past 3 months is $35.38.
-
Where Will Dyne Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dyne Therapeutics, Inc. share price will rise to $35.38 per share over the next 12 months.
-
What Do Analysts Say About Dyne Therapeutics, Inc.?
Analysts are divided on their view about Dyne Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dyne Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Dyne Therapeutics, Inc.'s Price Target?
The price target for Dyne Therapeutics, Inc. over the next 1-year time period is forecast to be $35.38 according to 13 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is DYN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dyne Therapeutics, Inc. is a Buy. 10 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DYN?
You can purchase shares of Dyne Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dyne Therapeutics, Inc. shares.
-
What Is The Dyne Therapeutics, Inc. Share Price Today?
Dyne Therapeutics, Inc. was last trading at $20.64 per share. This represents the most recent stock quote for Dyne Therapeutics, Inc.. Yesterday, Dyne Therapeutics, Inc. closed at $20.65 per share.
-
How To Buy Dyne Therapeutics, Inc. Stock Online?
In order to purchase Dyne Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get DYN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DYN
Sector
P/E ratio
--
23.66x
PEG ratio
-1.99x
-0.01x
P/B ratio
4.15x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
DYN
Sector
Revenue growth
--
4.85%
Earnings growth
20.87%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.84
-$0.20
Profitability
DYN
Sector
Profitability FY 2024
-$2.2M
$3.6M
Return on invested capital
-59.17%
-30.98%
Return on assets
-56.1%
-27.62%
Return on equity
-64.85%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
DYN
Sector
Total cash
$791.9M
$27.2M
Short term investments
$206.8M
$25.7M
Total assets
$691.2M
$79.9M
Long term debt
$115.4M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
